drugset / Trial / NCT07269106

Efficacy and Safety of Anrikefon for Postoperative Analgesia in Ophthalmic Surgery

NCT07269106

Phase 4 Recruiting 204 enrolled Zhongshan Ophthalmic Center, Sun Yat-sen University
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The goal of this clinical trial is to learn if Anrikefon works as well as nalbuphine to control postoperative pain in adults undergoing ophthalmic surgery under general anesthesia. It will also learn about the safety and recovery outcomes of using Anrikefon. The main questions it aims to answer are: * Does Anrikefon provide pain relief that is not inferior to nalbuphine after ophthalmic surgery? * Does Anrikefon cause fewer central side effects, such as sedation or dizziness, compared with nalbuphine? * Does Anrikefon help patients recover and get discharged faster after day-surgery procedures? Researchers will compare Anrikefon to nalbuphine to see if Anrikefon can offer effective and safer perioperative analgesia for ophthalmic day-surgery patients. Participants will: * Receive either an intravenous dose of Anrikefon or nalbuphine during surgery. * Be monitored for pain scores, side effects, and recovery parameters after surgery. * Complete follow-up assessments.

Timeline

Start
2026-01-22
Primary completion
2027-12-31
Completion
2027-12-31

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Anrikefon Unknown 1 ug/kg Intravenous
Comparator Nalbuphine Small molecule 0.1 mg/kg Intravenous

Indications

No indication recorded.